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We have previously identified mgrA (rat) as a regulator of autolysis in Staphylococcus aureus. Besides its effect
on autolytic activity, we recently found alterations in the expression of regulator and target virulence genes in
the mgrA mutant. Northern analysis and transcription fusion assays showed that inactivation of mgrA has led
to the downregulation of RNAIII of agr and hla and upregulation of sarS and spa. Although both SarA and agr
are activators of ␣-hemolysin and a repressors of protein A synthesis, we found that the transcription of sarA
was not affected in the mgrA mutant and vice versa, indicating that MgrA likely regulates hla and spa in a
SarA-independent manner. Previously we have shown that SarT, a SarA homolog, is a repressor of hla and an
activator of spa, presumably by activating SarS, however, analysis of the double sarT mgrA mutant for hla and
spa transcription indicated that the mgrA-mediated effect is not mediated via sarT. Our results further
demonstrated that the mgrA gene product regulates hla and spa expression in a dual fashion, with the first
being agr dependent and the second agr independent. In the agr-independent pathway, MgrA binds directly to
hla and the sarS promoter to modulate ␣-hemolysin and protein A expression. Thus, our studies here have
defined the nature of interaction of mgrA with other regulators such as agr, sarS, and sarT and its role in
regulating hla and spa transcription within the virulence regulatory network of S. aureus.
Staphylococcus aureus, a member of the family Micrococcaceae, is a gram-positive bacterium that normally colonizes
the epithelial surface in 30 to 40% of humans. Despite advances in antimicrobial therapy, S. aureus remains a major
cause of infections in the hospital setting. The spectrum of
diseases caused by this organism is extremely wide, ranging
from superficial skin infections to deep abscesses (29). Many of
these infections begin locally (skin and catheters) and subsequently spread to the bloodstream, putting patients at risk of
developing endocarditis and other metastatic complications
(45). The capacity to cause a myriad of infections is probably
attributable to the organism’s capacity to colonize and survive
in diverse host niches during the infection process.
The pathogenicity of S. aureus is a complex process involving
the spatial-temporal production of a diverse array of virulence
factors. Many cell wall components that act as adhesins (e.g.,
fibrinogen and fibronectin binding proteins) or contribute to
the evasion of host defense (protein A) are produced primarily
during the exponential phase while the production of toxins
and enzymes (alpha-hemolysin) that facilitate tissue invasion
occurs postexponentially (45).
Adding to this complexity in S. aureus pathogenesis is the
dramatic worldwide increase in antibiotic resistance among
clinical isolates. More than 90% of staphylococcal isolates are
now penicillin resistant. With the introduction of methicillin in
the 1960s, the percentage of methicillin-resistant S. aureus
infections has gradually increased, now up to 60 to 70% in the

hospital setting. In the past few years, community-acquired
methicillin-resistant S. aureus infections have been reported
with increased frequency (20). The increased use of vancomycin, a glycopeptide antibiotic, has led to the emergence of
vancomycin-resistant strains (4, 50). This has raised the concern that resistant S. aureus infections may be difficult to treat
with currently available antibiotics. Thus, there is a need to
understand the pathogenetic process so that new molecular
targets can be identified for the development of effective therapeutic agents.
The coordinated synthesis of cell wall proteins in the exponential phase and extracellular proteins during the postexponential phase suggests that many of these virulence determinants are governed by global regulatory elements (12).
Members of these regulatory systems include the SarA protein
family (8, 12) and a number of two-component regulatory
systems such as AgrAC (26), SaeRS (41, 19, 51), LytRS (3),
ArlRS (16), SrrAB (55), (44), YycFG (36), and VraRS (28).
The sarA and agr loci comprise two critical global regulatory
elements that coordinate synthesis of cell wall and extracellular
virulence proteins during the exponential and postexponential
phases, respectively (1, 12).
The agr locus encodes two divergent transcripts, RNAII and
RNAIII, driven by two distinct promoters, P2 and P3, respectively. The P2 transcript encodes four genes, agrB, agrD, agrC,
and agrA, comprising a two-component quorum-sensing system normally required for the activation of RNAII and
RNAIII (38, 42). The RNAII gene product AgrD encodes a
46-residue peptide which is processed and secreted as an autoinducing peptide with the aid of the putative membrane
component AgrB. This cyclic peptide carries a quorum-sensing
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TABLE 1. Strains and plasmids

Strain or plasmid

S. aureus
RN4220
RN6390

Comment

Reference or source

Mutant strain of 8325-4 that accepts foreign DNA
agr⫹ laboratory strain related to 8325-4, maintains hemolytic pattern when propagated
on sheep erythrocytes
Methicillin-resistant laboratory strain
Laboratory strain
Wild-type strain FDA486, sigB⫹, intact rsbU
agr mutant of RN6390 (⌬agr::tetM)
sarT mutant of RN6390 (⌬sarT::tetK)
mgrA mutant of RN6390 (⌬mgrA::ermC)
ALC2530 complemented with the mgrA gene in single copy
mgrA mutant of COL (⌬mgrA::ermC)
mgrA mutant of Newman (⌬mgrA::ermC)
mgrA mutant of FDA486 (⌬mgrA::ermC)
agr mgrA (deletion) double mutant of RN6390
sarT mgrA (deletion) double mutant of RN6390
agr sarT (deletion) double mutant
mgrA sarT agr (deletion) triple mutant

54
37
43
42
This
21
21
This
This
This
21
This
This
This

E. coli
XL-1 Blue
Inv␣F⬘

General-purpose host strain for cloning
Host strain for the TA cloning vector (pCR2.1)

31
Invitrogen

Plasmids
pCR2.1
pALC1484
pALC1740
pALC1741
pALC1743
pALC3179
pALC1594
pALC2321
pALC1996
pRN6735

E. coli PCR cloning vector
Derivative of pSK236 containing the promoterless gfpuvr gene
pALC1484 with hla promoter fragment
pALC1484 with spa promoter fragment
pALC1484 with P3 agr promoter fragment
pALC1484 with sarS promoter fragment
235-bp hla promoter region in pCR2.1
sarS promoter region in pCR2.1
agr P2–P3 promoter region in pALC1484
Contains promoterless RNAIII under control of the blaZ promoter

Invitrogen
25
27
27
25
This study
13
46
14
26

COL
Newman
FDA486
RN6911
ALC3043
ALC2530
ALC2531
ALC2542
ALC2547
ALC3632
ALC2537
ALC3046
ALC3188
ALC3191

function and, upon reaching the threshold level, binds to AgrC,
the membrane sensor component of a two-component system,
eventuating in the activation of the response regulator AgrA
(24, 23). Presumably, phosphorylated AgrA would bind to the
agr P3 promoter to promote transcription from the P3 promoter.
The P3 transcript, designated RNAIII, is the regulatory molecule of agr and acts on target genes mainly at the level of
transcription and, to a lesser extent, translation (42, 22). Once
RNAIII is synthesized, it somehow upregulates the transcription of exoprotein genes (e.g., hla) while downregulating genes
encoding cell wall proteins (e.g., spa, encoding protein A, and
fnb, encoding fibronectin binding protein) (22). However, the
exact manner by which RNAIII activates target gene transcription is not clearly defined.
The agr locus is also activated by SarA, which binds to the agr
P2-P3 promoter region to activate RNAII and RNAIII transcriptions (9, 13). The sarA locus is composed of three overlapping transcripts, sarA P1, P3, and P2, each encoding the
14.5-kDa SarA protein. GeneChip analysis indicated that the
sarA locus affects the transcription of ⬇120 genes in S. aureus
(2, 15). While the sarA and agr loci are the major controlling
elements for the expression of a variety of virulence proteins
during the growth cycle (1, 12), a number of SarA homologs
(members of the SarA protein family) have been found to
participate in the sarA and agr regulatory cascade (12, 5),

39
39

study
study
study
study
study
study
study

including SarT, a repressor of hla which is normally repressed
by SarA and agr (49), SarS, an activator of protein A synthesis
(10, 52), and SarU, which activates RNAIII transcription (33).
Remarkably, SarT was found to activate sarS expression (48),
indicating that agr may repress protein A expression by downregulating sarT and subsequently sarS.
In this study, we report the interaction of Rat/MgrA protein
with agr and its effect on the sarS and hla promoters, culminating in the expression of ␣-hemolysin and protein A. A
mutation in mgrA resulted in altered expression of RNAIII,
sarS, hla, and spa expression. We also provided additional
evidence that mgrA has a dual role in regulating hla and spa
expression. In the agr-dependent pathway, decreased agr transcription in mgrA mutants would lead to reduced hla transcription and an increase in spa transcription. In the agr-independent pathway, direct interactions of MgrA and hla with the
sarS promoter resulted in activation or repression of the respective gene. Based on these results, we propose MgrA to be
an important regulator of virulence determinants in S. aureus.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The bacterial strains and
plasmids used in this study are listed in Table 1. Phages ⌽11 and 80␣ were used
as transducing phages for S. aureus strains. S. aureus cells were grown at 37°C
with aeration in CYGP 03GL broth (39) or tryptic soy broth supplemented with
antibiotics as indicated. Luria-Bertani (LB) was used for cultivating Escherichia
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coli. Antibiotics used for S. aureus were erythromycin, 5 g/ml; tetracycline, 3
g/ml; chloramphenicol, 10 g/ml; and minocycline, 2.5 g/ml. For E. coli, the
following concentrations were used: ampicillin, 50 g/ml; and spectinomycin, 75
g/ml.
Genetic manipulations in E. coli and S. aureus. For the propagation of all
plasmid constructs, E. coli strain DH5␣ was used. Standard molecular biology
and recombinant DNA techniques were followed (31). S. aureus RN4220, a
restriction-deficient derivative of strain 8325–4 (39), was used as the initial
recipient for the transformation of plasmid constructs by electroporation (47).
The construction of the mgrA (rat) deletion mutant in the RN6390 background
to yield ALC2530 has been previously described (21). To generate mgrA deletion
mutants in other genetic backgrounds, we used ⌽11 and 80␣ phage lysates of
ALC2530 to infect strains COL, Newman, FDA486, RN6911 (agr mutant), and
ALC3043 (sarT mutant) (Table 1). For the construction of the sarT agr double
mutant (ALC3188), a ⌽11 phage lysate of the sarT mutant was used to infect the
agr mutant RN6911. Similarly the triple mgrA agr sarT mutant (ALC3191) was
constructed by infecting the mgrA sarT double mutant with a phage lysate of the
RN6911 agr mutant.
Isolation of RNA and Northern blot hybridization. Overnight cultures of S.
aureus were diluted 1:100 in CYGP and grown to late log (optical density at 650
nm [OD650] ⫽ 1.2) phase. The cells were harvested and processed with a Trizol
isolation kit (Gibco BRL, Gaithersburg, Md.) in combination with 0.1-mm sirconia-silica beads in a Biospec reciprocating shaker to yield RNA as described
(7); 15 g of each sample was electrophoresed in a 1.5% agarose–0.66 M
formaldehyde gel in morpholinepropanesulfonic acid (MOPS) running buffer (20
mM MOPS, 10 mM sodium acetate, 2 mM EDTA, pH 7.0). Blotting of RNA
onto Hybond N⫹ membranes (Amersham, Arlington Heights, Ill.) was performed with the Turboblotter alkaline transfer system (Schleicher & Schuell,
Keene, N.H.). For detection of specific transcripts (RNAIII, sarA, saeRS, sarS,
sarT, spa, hla, and mgrA), gel-purified DNA probes were radiolabeled with
[␣-32P]dCTP by the random-primed DNA labeling method (Roche Diagnostics
GmbH) and hybridized under aqueous-phase conditions at 65°C (6). The blots
were subsequently washed and autoradiographed as described (11).
Transcriptional fusion studies of different promoters linked to the gfpuvr
reporter gene. To confirm the effect of the mgrA mutation on promoter activities
of other regulators (RNAIII and sarS) and target genes such as hla and spa, we
cloned promoter fragments of these genes into the shuttle vector pALC1484
(pSK236-based plasmid containing the promoterless gfpuvr gene) upstream of the
gfpuvr gene to generate transcriptional fusions. Restriction analysis and DNA
sequencing confirmed the orientation and authenticity of the promoter fragments. The recombinant plasmids containing these promoters were first introduced into S. aureus strain RN4220 by electroporation (47). Plasmids purified
from RN4220 transformants were then electroporated into RN6390 and its
isogenic mgrA and other mutants.
After overnight culture, S. aureus strains harboring the recombinant plasmids
were diluted 1:100 and grown at 37°C with shaking in tryptic soy broth with
chloramphenicol (10 g/ml). Aliquots (200 l) were transferred hourly to microtiter plates to assay for cell density (OD650) and fluorescence for 10 h in a
FL600 fluorescence spectrophotometer (BioTek Instrument, Winooski, Vt.).
Promoter activities were plotted as mean fluorescence/OD650 ratio to minimize
variations due to cell density, using the average values from triplicate readings.
Gel shift assays. The purification of MgrA (Rat) protein has been described
(21). To determine if the recombinant MgrA protein binds to the agr and hla
promoters, a 228-bp fragment representing a region between the P2 and P3
promoters of agr (from nucleotides 1528 to 1756) (26) and a 235-bp hla promoter
fragment (nucleotides 1 to 80 plus 155 bp upstream of the start codon) (13) were
end-labeled with [␥-32P]ATP by using T4 polynucleotide kinase. Similarly, a
264-bp sarS promoter fragment (nucleotides 125169 to 125432) (10) obtained
from plasmid pALC2321 (Table 1) was end labeled. Labeled fragments (0.1 ng)
were incubated at room temperature for 20 min with various amounts of purified
MgrA protein in 25 l of binding buffer (25 mM Tris-HCl, pH 7.5, 0.1 mM
EDTA, 75 mM NaCl, 1 mM dithiothreitol, and 10% glycerol) containing 0.5 g
of calf thymus DNA per ml. The reaction mixtures were analyzed in a 6.0%
nondenaturing polyacrylamide gel. The band shifts were detected by exposing
dried gels to X-ray film.

RESULTS
Effect of the mgrA mutation on genes involved in virulence.
In an earlier study, we have reported that MgrA (Rat) is a
regulator of autolysis that shares sequence similarity with
members of the SarA and MarR families (21). As SarA is part
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of the complex regulatory network that modulates expression
of other regulators as well as target virulence genes, we wanted
to determine if MgrA constitutes part of this network by examining the effect of the mgrA mutation on known regulators
of virulence determinants.
We have focused on major regulators such as agr, sae, and
members of the SarA protein family (SarA, SarT, and SarS)
that are involved in the control of the ␣-hemolysin (hla) and
protein A (spa) genes, two putative virulence genes in S. aureus. Northern blot analysis revealed that the expression of hla
was reduced in the mgrA mutant compared with the parent
(RN6390), while the spa transcript level was increased (Fig.
1A). As sarA, sae, and agr were known to modulate hla and spa
transcription, we analyzed transcript levels of these regulatory
loci in the mgrA mutant of strain RN6390. Interestingly, the
transcript levels of sarA and saeRS, two known global regulators of virulence, were unchanged (Fig. 1B). In contrast, there
was a significant decrease in the mRNA level of RNAIII of agr
in the mutant compared with the parent, while the sarS level
was increased (Fig. 1C).
To confirm the effects of the mgrA mutation on RNAIII,
sarS, hla, and spa transcription, we transformed strain RN6390
and its isogenic mgrA mutant with shuttle plasmids carrying the
gfpuvr reporter gene driven by the RNAIII, sarS, hla, and spa
promoters. Green fluorescent protein (GFP) expression levels
in the mutant, expressed as fluorescence units per OD unit to
minimize the effect of bacterial concentration, confirmed the
Northern analysis data (Fig. 1A and 1C).
SarT is a known hla repressor that is normally repressed by
agr (49). Despite the finding that hla expression was downregulated in the mgrA mutant, we were not able to detect any
significant sarT transcript in the parent strain as well as in the
mgrA mutant. Promoter fusion studies also verified that sarT
was weakly expressed in the wild type and the mgrA mutant
(data not shown). Thus, SarT either does not play a major role
in the mgrA-mediated regulation of hla expression, or the low
level of sarT detection precludes us from discriminating the
contribution of sarT to hla regulation by mgrA (see below).
To ensure that these observations are not unique to the
mgrA mutant in the RN6390 background, we also ascertained
the presence of RNAIII, hla, and spa transcripts in other mgrA
mutants of strains COL, Newman, and FDA486. Our results
indicated that the mgrA mutants in all these genetic backgrounds displayed decreased levels of RNAIII and hla compared with the parent, while spa levels were increased (data not
shown). Taken together, these results showed that the mgrA
gene product modulates virulence gene expression by acting as
a positive regulator for RNAIII and hla and a negative regulator of spa.
Regulation of hla expression. Previous studies from our laboratory have shown that SarA and RNAIII of agr could activate hla expression directly, while SarA also modulates hla
transcription by repressing sarT (13, 49). Since MgrA positively
affects the expression of both agr (RNAIII) and hla, we wanted
to explore if this effect on hla by mgrA could be direct and/or
indirect via agr or the agr sarT pathway. To dissect these possibilities, a panel of double and triple deletion mutant strains
were constructed in strains RN6390 and Newman, including
mgrA sarT, mgrA agr, sarT agr, and mgrA sarT agr mutants
(described in Materials and Methods). All the mutants were
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FIG. 1. Effect of the mgrA mutation on the expression of genes
involved in virulence. A. Northern blot analysis of hla and spa transcripts in RN6390 and isogenic mgrA mutant ALC2530. The open
reading frame of each gene was used as a probe for the Northern blots.
RNA was harvested from cells grown to an OD650 of ⬇1.2, representing late exponential phase. The expression of GFP driven by the hla
and spa promoters in RN6390 and the mgrA mutant was also measured. Promoter activation was plotted as mean fluorescence/OD650
ratio, using average values of triplicate readings at an OD650 of ⬇1.4.
Comparable differences were also observed at earlier points. These
experiments were repeated at least three times with similar results. p,
RN6390; u, mgrA mutant ALC2530. B. Northern blot analysis of sarA
and saeRS transcripts in RN6390 and mgrA mutant ALC2530. The
open reading frame of each gene was used as a probe for the Northern
blots. RNA was harvested from cells grown to an OD650 of ⬇1.2,
representing late exponential phase. C. Northern blot analysis of agr
RNAIII and sarS transcripts in RN6390 and mgrA mutant ALC2530.
The probe for RNAIII was a 920-bp fragment containing the hld gene.
The open reading frame of the sarS gene was used as a probe for the
Northern blot. RNA was harvested from cells grown to an OD650 of
⬇1.2, representing late exponential phase. The expression of GFP
driven by the agr RNAIII and sarS promoters in RN6390 and the mgrA
mutant was also measured. Promoter activation was plotted as mean
fluorescence/OD650 ratio, using average values of triplicate readings at
an OD650 of ⬇1.4. Comparable differences were also observed at
earlier points. These experiments were repeated at least three times
with similar results. p, (RN6390; u, mgrA mutant ALC2530).
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confirmed by PCR and Southern blots. These strains were then
analyzed for RNAIII and hla expression.
As expected, the mRNA levels of RNAIII were not readily
detectable in the mgrA mutant and agr mutant, while RNAIII
expression in the sarT mutant was similar to that in the parental strain RN6390 (Fig. 2A). Analogous to the mgrA and agr
mutants, the remaining double and triple mutants did not
express RNAIII well. Interestingly, the mgrA mutant, coinciding with its low agr expression, expressed hla to a level similar
to that of the agr mutant. In the mgrA sarT double mutant, the
hla transcript level, concordant with a low level of RNAIII,
remained undetectable, indicating that activation of hla by
mgrA is not mediated via sarT (Fig. 2A and 2B). In the mgrA
agr double mutant, hla expression, similar to that of the single
mgrA and agr mutants, was significantly lower than that of the
parent (Fig. 2A and 2B). As expected, the expression of hla in
the triple mgrA sarT agr mutant remained low and not readily
detectable (Fig. 2A and 2B).
GFP fusion assays also confirmed these results (Fig. 2A and
2B), leading us to hypothesize that mgrA regulates hla indirectly via agr or directly on hla or both and that there is very
little cross talk, if any, between mgrA and sarT for hla expression.
Gel shift assay. By virtue of its homology with members of
the SarA and MarR protein families, we speculate that MgrA
might also be a DNA-binding protein (21). Given that an mgrA
mutation resulted in downregulation of RNAIII and hla, we
wanted to explore if MgrA binds to these promoters to modulate gene transcription. Using purified MgrA protein and
end-labeled hla promoter fragment (⬇1 ng), we found that
MgrA could bind to the 235-bp hla promoter fragment with 1
g of protein (Fig. 3A), while a nearly complete shift occurred
in the presence of 2.0 g of MgrA. The protein-DNA complex
could be disrupted with a 50-fold excess of unlabeled hla promoter fragment (lane 7 in Fig. 3A) but not with a 160-bp spa
promoter fragment (Fig. 3A, lane 9) or a nonspecific competitor such as a 300-bp asp23 promoter fragment at comparable
concentrations (Fig. 3A, lane 8).
Likewise, the mobility of the 228-bp end-labeled agr P2-P3
promoter fragment was also retarded by MgrA, with the retardation taking place at 1.5 g of protein (Fig. 3B). As with the
hla promoter fragment, unlabeled agr promoter fragment competed successfully for the binding of MgrA, whereas the spa
and asp23 promoter fragments did not (Fig. 3B). Collectively,
these data demonstrated that MgrA likely regulates hla and
RNAIII by interacting directly with the promoters. As RNAIII
of agr is known to regulate hla transcriptionally (42), these
results implied that MgrA could control hla expression both
directly and indirectly via agr.
Assessing hla expression by providing RNAIII in trans. To
further validate the role of agr in hla expression in mgrA mutants, we elected to complement the mgrA mutant with a plasmid carrying RNAIII (pRN6735). The cloned RNAIII fragment was under the control of a ␤-lactamase (blaZ) promoter
and constitutively expressed in the absence of pI524, the plasmid that carried the ␤-lactamase repressor (26). Plasmid
RN6735 was used to transform parental strains RN6390 and
Newman and isogenic mgrA and agr mutants. Restriction analysis confirmed the presence of plasmid RN6735 in the resultant
transformants. These transformants were then analyzed by
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FIG. 2. Transcription of agr RNAIII and hla in RN6390 and isogenic mutants. A. Northern blot analysis of agr RNAIII transcripts in RN6390
and isogenic mutants. The probe for RNAIII was a 920-bp fragment containing the hld gene. RNA was harvested from cells grown to an OD650
of ⬇1.2, representing late exponential phase. The expression of GFP driven by the agr RNAIII (P3) promoter was also measured. Promoter activation
was plotted as mean fluorescence/OD650 ratio, using average values of triplicate readings at an OD650 of ⬇1.4. This experiment was repeated at least three
times with similar results. p, RN6390; u, mgrA mutant ALC2530; `, sarT mutant ALC3043; s, agr mutant RN6911; z, sarT mgrA mutant ALC3046; t,
agr mgrA mutant ALC2537; ■ agr sarT mutant ALC3188; and 䊐 mgrA sarT agr mutant ALC3191. B. Northern blot analysis of the hla transcript in
RN6390 and isogenic mutants. The probe for hla was an 800-bp fragment encompassing the open reading frame. RNA was harvested from cells grown
to an OD650 of ⬇1.2, representing late exponential phase. The expression of GFP driven by the hla promoter was also measured. Promoter activation
was plotted as mean fluorescence/OD650 ratio, using average values of triplicate readings at an OD650 of ⬇1.4. This experiment was repeated at least three
times with similar results. p, RN6390; u, mgrA mutant ALC2530; `, sarT mutant ALC3043; s, agr mutant RN6911; z, sarT mgrA mutant ALC3046; t,
agr mgrA mutant ALC2537; ■ agr sarT mutant ALC3188; and 䊐 mgrA sarT agr mutant ALC3191.

Northern blotting to determine the levels of RNAIII and hla
expression.
Our results indicated that RNAIII, as driven by the blaZ
promoter, was expressed constitutively in the wild-type strain
as well as in the mgrA and agr mutants (Fig. 4). Despite the
presence of RNAIII in induced mgrA and parental strains, the
expression of hla, while activated, was lower in the mgrA mutants than in the parents in both the RN6390 and Newman
backgrounds (lanes 2 and 4 and lanes 6 and 8 in Fig. 4).
Collectively, gel shift and transcriptional data with RNAIII
provided in trans showed that mgrA-regulation of hla is likely
under bimodal control, with both direct (hla promoter) and
indirect (agr promoter) regulation.

Regulation of protein A by mgrA is dependent on sarS. As
described earlier (Fig. 1A), mgrA also modulates protein A
expression negatively. Previously, the expression of spa has
been shown to be positively regulated by sarS (52, 10). Additional gel shift and transcriptional studies revealed that sarS is
positively controlled in part by sarT and negatively controlled
by agr (48, 33). As the mgrA locus positively controls agr, we
wanted to ascertain if mgrA also represses sarS and spa expression via agr. To ascertain this pathway, we used the same set of
strains that we used to dissect the regulation of hla.
Northern blotting data revealed that the sarS transcript
level, as expected, was not readily detectable in the parent but
was increased in the mgrA mutant (Fig. 5A). Interestingly, the

FIG. 3. Gel shift assays of purified MgrA with hla and agr promoter
fragments. MgrA protein in increasing concentrations was incubated
with end-labeled hla or agr promoter fragments. In competition assays,
MgrA protein (1,500 ng) was incubated with the promoter fragment in
the presence of a 50-fold excess of unlabeled specific competitor (hla
or agr) (lane 7) or nonspecific competitors (⬇300-bp asp23 promoter in
lane 8 and ⬇160-bp spa promoter fragment in lane 9).

FIG. 4. Transcription of hla by providing RNAIII in trans. Northern blot analysis of agr RNAIII and hla transcripts in strains with and
without plasmid RN6735. (Transformants are indicated as strain/Pl.)
RNA was harvested from cells grown to an OD650 of ⬇1.2, representing late exponential phase.
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FIG. 5. Transcription of sarS in RN6390 and isogenic mutants. A.
Northern blot analysis of the sarS transcript in RN6390 and isogenic
mutants. The open reading frame of sarS was used as a probe. RNA
was harvested from cells grown to an OD650 of ⬇1.2, representing late
exponential phase. B. The expression of GFP driven by the sarS promoter was also measured. Promoter activation was plotted as mean
fluorescence/OD650 ratio, using average values of triplicate readings at
an OD650 of ⬇1.4. This experiment was repeated at least three times
with similar results. p, RN6390; u, mgrA mutant ALC2530; `, sarT
mutant ALC3043; s, agr mutant RN6911; z, sarT mgrA mutant
ALC3046; t, agr mgrA mutant ALC2537; ■ agr sarT mutant ALC3188;
and 䊐 mgrA sarT agr mutant ALC3191.

increase in sarS promoter activity, as assessed by transcriptional fusions, was higher in the mgrA mutant than in the agr
mutant, implying an additional effect on sarS by mgrA other
than those of agr (Fig. 5B). As expected in the absence of sarT,
there was little if any sarS transcription (48). These observations were confirmed by promoter fusion assays (Fig. 5B).
Interestingly, in the double mgrA sarT mutant and triple mgrA
sarT agr mutant, the sarS transcript level remained high, suggesting that the effect of mgrA on sarS is not mediated via sarT.
Likewise, in the mgrA agr mutant, sarS levels continued to be
elevated. In contrast, the effect of agr on sarS is sarT dependent, as exemplified by the near absence of sarS transcription
in the sarT agr mutant. Collectively, these results indicate that
modulation of sarS expression by mgrA is not mediated via sarT
and is only partially dependent on agr.
To correlate sarS to spa expression, we also analyzed spa
expression in the above mutants. Our results indicated that the
spa mRNA level in all these strains corresponded quite nicely
with the sarS levels (Fig. 6A), with upregulation in the mgrA,
mgrA sarT, mgrA agr, and mgrA agr sarT mutants and downregulation or relatively unaltered levels in sarT and agr sarT
mutants, using both Northern and transcriptional fusion assays
(Fig. 6A and B).
The observation that mgrA may impact on sarS independent
of agr and sarT led us to speculate that a direct interaction
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FIG. 6. Transcription of spa in RN6390 and isogenic mutants. A.
Northern blot analysis of the spa transcript in RN6390 and isogenic
mutants. The open reading frame of spa was used as a probe. RNA was
harvested from cells grown to an OD650 of ⬇1.2, representing late
exponential phase. B. The expression of GFP driven by the spa promoter was also measured. Promoter activation was plotted as mean
fluorescence/OD650 ratio, using average values of triplicate readings at
an OD650 of ⬇1.4. This experiment was repeated at least three times
with similar results. p, RN6390; u, mgrA mutant ALC2530; `, sarT
mutant ALC3043; s, agr mutant RN6911; z, sarT mgrA mutant
ALC3046; t, agr mgrA mutant ALC2537; ■ agr sarT mutant ALC3188;
and 䊐 mgrA sarT agr mutant ALC3191.

between MgrA and the sarS promoter may occur. Gel shift
assays with labeled sarS promoter (240 bp) and purified MgrA
protein showed that 750 g of MgrA was required to retard the
mobility of the sarS promoter (Fig. 7). At 2,000 g, there was
a complete shift of the promoter DNA in the gel shift assay.
The protein-DNA complex could be disrupted by 50-fold excess unlabeled promoter DNA (Fig. 7) while the nonspecific
promoter DNA fragments, including the spa and asp23 promoters, did not alter the binding of MgrA to the sarS promoter
(Fig. 7). Seen together, these data showed that MgrA likely
acts as a negative regulator of spa by repressing sarS expression.

FIG. 7. Gel shift assays of purified MgrA with sarS promoter fragment. MgrA protein in increasing concentrations was incubated with
the end-labeled sarS promoter fragment. In competition assays, MgrA
protein (1,000 ng) was incubated with end-labeled promoter in the
presence of a 50-fold excess of unlabeled specific competitor (sarS)
(lane 7) or the nonspecific competitor (⬇300-bp asp23 promoter in
lane 8 and the ⬇160-bp spa promoter fragment in lane 9).
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FIG. 8. Transcription of spa by providing RNAIII in trans. Northern blot analysis of the spa transcript in strains with and without
plasmid RN6735. (Transformants are indicated as strain/Pl.) The open
reading frame of the spa gene was used as a probe. RNA was harvested
from cells grown to an OD650 of ⬇1.2, representing late exponential
phase.

To assess if the absence of RNAIII could account for the
overexpression of sarS and hence spa in the mgrA mutant, we
also provided RNAIII in trans with a plasmid containing the
RNAIII sequence in these strains. The strains were then evaluated for spa expression by Northern blotting. Our results
indicated that overexpression of RNAIII under the ␤-lactamase promoter led to significant repression of spa in the mgrA
mutants of strains RN6390 and Newman compared with the
mgrA mutant controls (Fig. 8). These data imply that MgrA
likely has a dual role in regulating spa expression, with the first
pathway dependent on agr, wherein an absence of RNAIII in
an mgrA mutant leads to an increase in sarS and ultimately spa
expression. In the second pathway, a direct interaction between MgrA and the sarS promoter likely occurs to repress
sarS transcription.
DISCUSSION
With the advance of genomic information coupled with transcriptional analysis, it is now recognized that a complex regulatory network exists to control growth phase-dependent expression of a number of virulence determinants (1, 15, 40). The
major players within this network appear to be the two-component systems (e.g., agrAC, saeRS, arlRS, and srrAB) and
members of the SarA protein family (8, 12, 16, 18, 26, 44).
Based on structure and sequence alignment, the SarA protein
family can be divided into three subfamilies: the single-domain
proteins (e.g., SarA and SarR), the double-domain proteins
(e.g., SarS and SarU), and the MarR homologs (e.g., MgrA).
In previous studies (11, 32), we have shown that members of
the single-domain (SarR on sarA expression) and double-domain (SarS on spa expression) proteins participate in the modulation of virulence determinants. The first member of the
third SarA subfamily, MgrA, was originally identified as an
important regulator of autolytic activity in S. aureus (21, 35).
We have now characterized mgrA further with regard to the
expression of virulence determinants and conclude that all
three SarA subfamilies likely participate in the virulence regulatory network.
We have examined in this study four prototypic S. aureus
strains, including RN6390, Newman, FDA486, and COL. Inactivation of mgrA in all these strains has led to downregulation of RNAIII of agr, decreased expression of hla, and upregulation of sarS and spa (Fig. 1 and 2). Phenotypically,
decreased expression of hla and upregulation of spa in an mgrA
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mutant is consistent with an agr mutant phenotype. However,
the effect of mgrA on intermediate regulatory genes such as
sarS and sarT downstream of agr as well as target genes (direct
versus indirect effect) has not been previously defined. In addition, we have also found that the transcription of sarA, an
important regulatory locus that partially controls agr, is not
affected in the mgrA mutant, suggesting that mgrA likely regulates hla and spa in a SarA-independent manner.
Regulation of hla expression in S. aureus is not mediated by
a single locus but is multifaceted. In particular, regulators such
as sarA, agr, and sae have been shown to upmodulate hla
expression both directly and indirectly (5, 13, 17, 22, 42, 51),
while sarT downregulates it (49). Similarly, spa expression is
repressed by sarA and agr and promoted by sarT and sarS ( 10,
48, 52,). Added to this list now is mgrA, which is part of the
regulatory cascade that controls agr and sarS to modulate hla
and spa expression.
Analysis of the double sarT mgrA mutant (ALC3046) for hla
transcription indicated that the mgrA-mediated effect did not
occur via sarT. Likewise, this effect is also independent of sae,
as sae transcription was unaltered in the mgrA mutant (Fig.
1B). While it would seem that reduced expression of RNAIII
in the mgrA mutant would account for the downmodulation in
hla expression, our finding that the hla transcript level in the
mgrA agr double mutant (ALC2537) was lower than in the agr
mutant (Fig. 2B) would suggest a dual effect of mgrA on hla.
The dual mode of regulatory control by mgrA on hla was
confirmed by gel shift assays (Fig. 3) as well as transcriptional
analysis of the mgrA mutant with RNAIII provided in trans
(Fig. 4). Thus, the mgrA gene product acts as a positive regulator for agr to promote hla transcription as well as binds to the
hla promoter to augment gene transcription.
In a previous study, Luong et al (30) also discovered mgrA in
a Tn917 transposon screen, searching for mutants that had
altered capsular production in cap8⫹ strain Becker. Contrary
to our finding here, they reported upregulation of alpha toxin
and protein A synthesis in an mgrA mutant of strain Becker;
unfortunately, the impact of mgrA on the expression of agr
RNAIII was not evaluated in detail in that study. Because of
this discrepancy, we sought to analyze RNAIII and hla expression in isogenic mgrA strains in four different genetic backgrounds, including RN6390, Newman, COL, and FDA486. All
of the aforementioned mgrA mutants exhibited reduced levels
of agr and hla expression compared with their parental counterparts. We have also analyzed hla transcription in the mgrA
mutant of Becker and found no significant increase in the
transcript level compared with the parental strain; transcriptional fusion studies with the hla promoter also confirmed the
Northern blot results (data not shown). In distinction to our
transcriptional approach, Luong et al. studied the phenotypic
effect of mgrA on alpha-toxin production by hemolytic assays
on blood agar plates. Whether altered levels of V8 protease as
reported in the original mgrA mutant (21) account for the
increase in alpha-toxin in the Becker strain is not clear. However, in subsequent experiments in which Luong et al. transduced the mgrA mutation from strain Becker to Newman, they
also found reduced levels of ␣-hemolysin production and elevated levels of protein A synthesis (unpublished data). Thus,
differences in the genetic background may have accounted for
the divergent results. Although we previously were able to
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have now added to this spectrum of effects the ability of mgrA
to positively regulate agr as well as its direct effect on hla and
sarS, eventually yielding what appears to be an agr-negative
phenotype in an mgrA mutant. Given that mgrA is a negative
regulator of autolysis and a positive regulator of agr, it seems
logical that interference with MgrA may be a reasonable antiinfective strategy, since this approach would promote autolysis
while minimizing the expression of agr, an important regulator
of virulence determinants in S. aureus.
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